ArticleIrish journal of medical science2022
MiR-590-3p and its targets VEGF, PIGF, and MMP9 in early, middle, and late pregnancy: their longitudinal changes and correlations with risk of fetal growth restriction.
Article in Irish journal of medical science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Circulating miRNAs in the first trimester and pregnancy complications: a systematic review.Epigenetics · 2023Pooled it
- Fatty acid composition in the yolk and yolk sac, embryo development, IGF-I and VEGF-A gene expressions and hatching results in eggs obtained from local and commercial breeders.Tropical animal health and production · 2026Article
- Differential Expression of Maternal Plasma microRNAs and Their Respective Gene Targets Can Predict Early Fetal Growth Restriction.Life (Basel, Switzerland) · 2025Review
- Article
- Differential Effects ofNutrients · 2024Article
- Value of Non-Coding RNA Expression in Biofluids to Identify Patients at Low Risk of Pathologies Associated with Pregnancy.Diagnostics (Basel, Switzerland) · 2024Review
- Eucommia granules activate Wnt/β-catenin pathway, and improve oxidative stress, inflammation, and endothelial injury in preeclampsia rats.Acta cirurgica brasileira · 2024Article
- Biomarkers for Diagnosing and Treating Fetal Growth Restriction.Current medicinal chemistry · 2024Review
- Identification of miRNAs Involved in Foetal Growth Restriction Due to Maternal Smoking during Pregnancy.Journal of clinical medicine · 2022Article
- Article
- The Role of Syncytin in Placental Angiogenesis and Fetal Growth.Frontiers in cell and developmental biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe term "fetal growth restriction (FGR)" is commonly used to describe fetuses with an estimated fetal weight that is less than 10th percentile for gestational age. This study aimed to investigate the longitudinal change of microRNA-590-3p (miR-590-3p), vascular endothelial growth factor (VEGF), placental growth factor (PIGF), and matrix metalloproteinase (MMP)9 expressions in early, middle, and late pregnancy, and their correlations with the fetal growth restriction (FGR) risk.
methodsTotally, 970 pregnant women in early pregnancy were enrolled, and their plasma samples were, respectively, acquired in early pregnancy (at 10th or 11th week of gestational age), middle pregnancy (at 20th or 21st week of gestational age), and late pregnancy (at 33th or 34th week of gestational age) for miR-590-3p, VEGF, PIGF, and MMP9 determinations.
resultsMiR-590-3p underwent a growing trend, but VEGF, PIGF, and MMP9 experienced declined trend along with pregnancy (all P < 0.001). Furthermore, the negative association of miR-590-3p with VEGF, PIGF, and MMP9 became stronger along with the pregnancy. Besides, miR-590-3p expression in middle and late pregnancy was higher, but VEGF, PIGF, and MMP9 expressions in middle and late pregnancy were lower in women affected by FGR compared to normal pregnant women (all P < 0.001). In addition, miR-590-3p, VEGF, PIGF, and MMP9 expression in middle and late pregnancy were of good value in predicting FGR risk.
conclusionsmiR-590-3p exhibits a growing trend during pregnancy, and its expression in middle and late pregnancy is associated with increased FGR risk via interaction with VEGF, PIGF, and MMP9.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.